A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.

F. Lacour; J. Lacour; A. Spira; M. Michelson; G. Delage; J. Y. Petit; J. Viguier

A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.

F. Lacour, J. Lacour, A. Spira, M. Michelson, G. Delage, J. Y. Petit, J. Viguier

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.

Original language	English
Pages (from-to)	200-206
Number of pages	7
Journal	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Volume	80
Publication status	Published - 1982

ASJC Scopus subject areas

Medicine(all)

Fingerprint Dive into the research topics of 'A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.'. Together they form a unique fingerprint.

Cite this

A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer. / Lacour, F.; Lacour, J.; Spira, A.; Michelson, M.; Delage, G.; Petit, J. Y.; Viguier, J.

In: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, Vol. 80, 1982, p. 200-206.

Research output: Contribution to journal › Article › peer-review

@article{0692ebfc3f1c494aaeca49474d2fd905,

title = "A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.",

abstract = "Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.",

author = "F. Lacour and J. Lacour and A. Spira and M. Michelson and G. Delage and Petit, {J. Y.} and J. Viguier",

year = "1982",

language = "English",

volume = "80",

pages = "200--206",

journal = "Recent Results in Cancer Research",

issn = "0080-0015",

publisher = "Springer New York",

}

TY - JOUR

T1 - A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.

AU - Lacour, F.

AU - Lacour, J.

AU - Spira, A.

AU - Michelson, M.

AU - Delage, G.

AU - Petit, J. Y.

AU - Viguier, J.

PY - 1982

Y1 - 1982

N2 - Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.

AB - Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.

UR - http://www.scopus.com/inward/record.url?scp=0020006770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020006770&partnerID=8YFLogxK

M3 - Article

C2 - 7036283

AN - SCOPUS:0020006770

VL - 80

SP - 200

EP - 206

JO - Recent Results in Cancer Research

JF - Recent Results in Cancer Research

SN - 0080-0015

ER -

A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.

Abstract

ASJC Scopus subject areas

Other files and links

Cite this